Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Agreement for the manufacturing and commercialization of Huperzine-A.

Shasun Pharmaceuticals Ltd and Debiopharm Group™ (Debiopharm) have entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.

Huperzine-A is a potent and reversible acetylcholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer’s disease. Huperzine-A is commercially available through Shasun Pharmaceuticals.

According to the terms of the agreement, Shasun Pharmaceuticals Ltd will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets.

The manufacturing technology involves a 10-stage chemical synthesis process including a complex chiral organometallic step as a key transformation of the Huperzine-A structure.

The synthesis is a result of a joint collaboration between Shasun’s research centers in Chennai and the UK.

This technology was recently recognized and awarded at the North East of England Process Industry Cluster (NEPIC), Innovation Awards in 2012.

NEPIC is a stand-alone company created to represent the 500+ Pharmaceutical, Biotechnology, Specialty Chemical, Polymer & Rubber, Petrochemical & Commodity Chemical companies based in the North East of England.

Commenting on the agreement, Dr Mauvernay, President and founder of Debiopharm Group™ said, “We are delighted to continue our collaboration with Shasun Pharmaceuticals Ltd. Clinical studies have demonstrated the drug to enable significant improvement in both memory deficit and cognitive performance and we are excited to have the opportunity to add value to this technology while contributing to improve people’s quality of life.”

Dr Michel Spagnol, President of Shasun Pharmaceuticals Ltd added, “We are very proud of this achievement, resulting from a very close collaboration with Debiopharm. It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Debiopharm and TCGLS Enter Into an Exclusive Research Agreement
Collaboration to develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm.
Tuesday, September 10, 2013
Debiopharm and Ascepion Announce an Exclusive License Agreement
Agreement for the development and commercialization of the dual-targeting kinase Inhibitor, ASP-08126 (Debio 1144), for the treatment of oncology diseases.
Tuesday, June 19, 2012
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.
Tuesday, February 21, 2012
Debiopharm and Aurigene Sign Agreement for the Development and Commercialization of Debio 1142
The Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours.
Wednesday, April 27, 2011
Debiopharm Group™ Starts Phase I Clinical Trial with Debio 0932
A targeted small molecule inhibitor of heat shock protein 90 for cancer treatment.
Wednesday, April 28, 2010
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl® to Further Help Prostate Cancer Patients
Debiopharm Group announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl® (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Thursday, September 25, 2008
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!